Proteflazid drops 30ml

Proteflazid pharmachologic effect:
The preparation includes flavonoids wild grasses Calamagrostis epigeios and Deschampsia caespitosa L. L., capable of inhibiting the DNA polymerase and thymidine kinase (enzyme specific viruses) into cells that are infected with virus. Inhibition of these enzymes leads to the cessation of DNA replication of the virus, which makes impossible reproduction of the virus. Furthermore Proteflazid enhances innate immunity, increasing the level of endogenous interferon, which improves the resistance of the organism, not only to viruses and bacteria. The drug has antioxidant properties, preventing the accumulation of lipid peroxidation products.

Indications:
1. Treatment of infections caused by viruses:
- Herpes 1 and type-2 (herpes stomatitis, genital herpes, herpes conjunctivitis, shingles and other diseases caused by the herpes virus);
- Hepatitis B and C, the drug is used in the complex therapy;
2. Prevention of viral and bacterial diseases in people with decreased immune status (HIV, AIDS, primary and secondary immunodeficiencies).

Proteflazid mode of application:
Proteflazid comes in the form of drops, so before receiving the drug should be put on a piece of sugar or a piece of bread. Take as follows: 1 Week 15 drops per day by dividing the daily dose into 3 doses (5 drops per dose), 2-3 weeks -30 drops into 3 doses (10 drops per dose), with 4 24 th week of drops, divided into 3 doses (8 drops per reception). The course of treatment 1 month, 4 weeks can repeat the course.
Children under 1 year old drug is given at a dose of 1 drop per day, from 1 to 2 years dose is 2 drops, divided into 2 doses (1 drop at the reception); from 2 to 4 years old: Week 1 - 2 drops per day, divided into 2 doses (1 drop at the reception), Week 2 - 4 drops per day, divided into 2 doses (2 drops per reception); from 4 to 6 years old: Week 1 - 6 drops per day, divided into 3 doses (2 drops per reception), Week 2 - 9 drops a day, dividing the daily dose for 3 doses (3 drops at the reception ); from 6 to 9 years old: Week 1 - 9 drops daily, divided dose for 3 doses (3 drops per reception), 2nd week 18 drops per day, divided into 3 doses (6 drops per reception); from 9 to 12 years: 1st week - 12 drops per day, divided into 3 doses (4 drops per reception), Week 2 - 21 drop per day, divided into 3 doses (7 drops per reception); 12 years: 1st week - 15 drops, divided into 3 doses (5 drops per reception), from the 2nd week - 24 drops, divided into 3 doses (8 drops per reception).
Children under the age of 6 years, the necessary dose is recommended to be dissolved in 50 ml of water with sugar.
With frequent relapses of infection must be conducted in the course of 3-4 years, as follows: 15 drops by dividing into 3 doses (5 drops per dose) for 3 days, then 21 drop per day, divided into 3 doses (7 drops per dose) for 3 days, then another 3 months 24-30 drops per day, divided into 3 doses (8-10 drops per dose), then it is recommended to supportive therapy to 20 drops per day by dividing by 2 doses (10 drops per dose), for 2-4 months. When a latent infection throughout therapy with courses carried out 2 times a year.
In the treatment of hepatitis B and C, the drug is used as follows: 1 to Day 3 - 9 drops per day, divided into 3 doses (3 drops per dose), with 4 to 6 day 15 drops per day, divided into 3 receiving (5 drops per dose), from day 7 to 30 drops per day, divided into 3 doses (10 drops per dose), 4-6 months of treatment.
Proteflazid can be used topically for the treatment of herpetic lesions of the skin and mucous membranes, it is necessary to dissolve 1.5 ml in 10 ml 0.9% NaCl, in the form of lotions apply to the affected area 3-5 times a day. For genital herpes Proteflazid can be applied in the form of vaginal tampons. To do this, a solution of 3 ml in 20 ml 0.9% NaCl, moistened gauze and inserted into the vagina, the procedure is performed twice a day, if there is a burning sensation, it is necessary to change the proportions of the solution, doubling the amount of NaCl. The course of treatment for at least 14 days.

Proteflazid side effects:
Possible dyspepsia, transient increase in temperature, generally for 3-10 hours drug therapy that requires a change in dose.
Allergic reactions are rare and are on their own without treatment.

Proteflazid contraindications:
Intolerance to any of the components of the drug, gastric ulcer or duodenal ulcer during the exacerbation.

Proteflazid during pregnancy:
During pregnancy, in any trimester, used with caution, commensurate possible benefit to the mother and the potential risk for the baby.

Interaction with other drugs:
No adverse effects when combined with other drugs have been identified. In some cases it is optimal reception Proteflazid and antibiotics.

Overdose:
Overdose cases are not registered.

Product:
Container with 30 ml.

Storage conditions of Proteflazid:
Store in a place protected from sunlight, at a temperature of 15-25 degrees Celsius.
Changes in the structure at a gel-like, does not indicate a decrease in the effectiveness of the drug.

Composition:
100 ml of the preparation contains at least 32 mg, based on the flavonoid rutin; at least 3 0mg amount of carboxylic acids in terms of malic acid, derived from wild grasses Calamagrostis epigeios Deschampsia caespitosa L. and L.
Additional ingredients: ethyl alcohol 96%.

Proteflazid pharmacological group:
Antimicrobial and antiparasitic drugs
Antiviral drugs
Antiviral drugs other groups

Nosological classification (ICD-10):
Anogenital herpes virus infection [herpes simplex] (A60)
Herpetic eczema (B00.0)
Herpetic vesicular dermatitis (B00.1)
Herpetic gingivostomatitis and faringotonzilit (B00.2)
Herpes encephalitis G05.1 * (B00.4)
Herpetic eye disease (B00.5)
Other forms of herpes infection (B00.8)
Herpes infection, unspecified (B00.9)
Acute hepatitis B (B16)
Acute hepatitis C (B17.1)
Opayasyvayuschy shingles [herpes zoster] (B02)
The disease is caused by the human immunodeficiency virus [HIV] (B20-B24)
Immunodeficiency with predominantly antibody deficiency (D80)
Combined immunodeficiency (D81)
Immunodeficiency associated with other major defects (D82)
Common variable immunodeficiency (D83)
Other immunodeficiencies (D84)
Other disorders involving the immune mechanism, not elsewhere classified (D89)

ATC: J05AX

Additionally:
When using Proteflazid, in the treatment of hepatitis B and C in 10-15% of patients may increase the level transamina that does not require withdrawal of the drug, and does not affect its effectiveness.